Akari Therapeutics PLC said it fell out of compliance with a Nasdaq listing requirement after failing to file its annual report for the year ended Dec. 31, 2017, on time.

The biopharmaceutical company has until Nov. 12 to regain compliance.

Akari's CEO recently resigned following an internal investigation that revealed he used the company's credit card for personal use.

Akari said it found David Solomon violating the drugmaker's policies after incurring personal charges on the company's corporate credit cards.